These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 26635087)

  • 1. Advance of the application of nano-controlled release system in ophthalmic drug delivery.
    Wang X; Wang S; Zhang Y
    Drug Deliv; 2016 Oct; 23(8):2897-2901. PubMed ID: 26635087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled and continuous release ocular drug delivery systems: pros and cons.
    Abdelkader H; Alany RG
    Curr Drug Deliv; 2012 Jul; 9(4):421-30. PubMed ID: 22640036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomaterials for ocular drug delivery.
    Liu S; Jones L; Gu FX
    Macromol Biosci; 2012 May; 12(5):608-20. PubMed ID: 22508445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases.
    Durgun ME; Güngör S; Özsoy Y
    J Ocul Pharmacol Ther; 2020; 36(6):323-341. PubMed ID: 32310723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotechnology in ocular drug delivery.
    Sahoo SK; Dilnawaz F; Krishnakumar S
    Drug Discov Today; 2008 Feb; 13(3-4):144-51. PubMed ID: 18275912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent patents on ophthalmic nanoformulations and therapeutic implications.
    Ako-Adounvo AM; Nagarwal RC; Oliveira L; Boddu SH; Wang XS; Dey S; Karla PK
    Recent Pat Drug Deliv Formul; 2014; 8(3):193-201. PubMed ID: 25262835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo evaluation of in situ gelling systems for sustained topical ophthalmic delivery: state of the art and beyond.
    Destruel PL; Zeng N; Maury M; Mignet N; Boudy V
    Drug Discov Today; 2017 Apr; 22(4):638-651. PubMed ID: 28017837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug delivery to the posterior segment of the eye.
    Fischer N; Narayanan R; Loewenstein A; Kuppermann BD
    Eur J Ophthalmol; 2011; 21 Suppl 6():S20-6. PubMed ID: 23264325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Particle-based technologies for osteoarthritis detection and therapy.
    Kavanaugh TE; Werfel TA; Cho H; Hasty KA; Duvall CL
    Drug Deliv Transl Res; 2016 Apr; 6(2):132-47. PubMed ID: 25990835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart targeted nanoliposomal/nanoparticles drug delivery: An updated review.
    Cheraghi M; Negahdari B; Daraee H; Eatemadi A
    Biomed Pharmacother; 2017 Feb; 86():316-323. PubMed ID: 28011379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in ocular drug delivery.
    Achouri D; Alhanout K; Piccerelle P; Andrieu V
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1599-617. PubMed ID: 23153114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent patents on ocular drug delivery systems.
    Conway BR
    Recent Pat Drug Deliv Formul; 2008; 2(1):1-8. PubMed ID: 19075892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nano-ophthalmology: Applications and considerations.
    Kamaleddin MA
    Nanomedicine; 2017 May; 13(4):1459-1472. PubMed ID: 28232288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contact lenses as drug-delivery systems: a promising therapeutic tool.
    Holgado MA; Anguiano-Domínguez A; Martín-Banderas L
    Arch Soc Esp Oftalmol (Engl Ed); 2020 Jan; 95(1):24-33. PubMed ID: 31420118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review on therapeutic contact lenses for ocular drug delivery.
    Maulvi FA; Soni TG; Shah DO
    Drug Deliv; 2016 Oct; 23(8):3017-3026. PubMed ID: 26821766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Ocular Drug Delivery Systems: An Update on Microemulsions.
    Üstündağ Okur N; Çağlar EŞ; Siafaka PI
    J Ocul Pharmacol Ther; 2020; 36(6):342-354. PubMed ID: 32255728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nano-formulations of drugs: Recent developments, impact and challenges.
    Jeevanandam J; Chan YS; Danquah MK
    Biochimie; 2016; 128-129():99-112. PubMed ID: 27436182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research progress of ophthalmic preparations of immunosuppressants.
    Liu Y; Xu H; Yan N; Tang Z; Wang Q
    Drug Deliv; 2023 Dec; 30(1):2175925. PubMed ID: 36762580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug delivery.
    Shen HH; Chan EC; Lee JH; Bee YS; Lin TW; Dusting GJ; Liu GS
    Nanomedicine (Lond); 2015; 10(13):2093-107. PubMed ID: 26096379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in intraocular sustained-release drug delivery devices.
    Cao Y; Samy KE; Bernards DA; Desai TA
    Drug Discov Today; 2019 Aug; 24(8):1694-1700. PubMed ID: 31173915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.